Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Boarda€“Blinded 15-Month Study

Carmela Benson; H. Lynn Starr; Jean-Pierre Lindenmayer; Kimberly Cheshire-Kinney; Larry Alphs; Lian Mao; Stephen C. Rodriguez

首页> 外文期刊>Primary care companion to the journal of clinical psychiatry >Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Boarda€“Blinded 15-Month Study

【24h】

Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Boarda€“Blinded 15-Month Study

机译：精神分裂症中帕潘立酮棕榈酸酯与每日口服抗精神病药物治疗的实际结果：随机，开放标签，审查委员会–盲法为期15个月的研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Primary care companion to the journal of clinical psychiatry》 |2015年第5期|共页
作者
Carmela Benson; H. Lynn Starr; Jean-Pierre Lindenmayer; Kimberly Cheshire-Kinney; Larry Alphs; Lian Mao; Stephen C. Rodriguez;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献

1. Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Board-Blinded 15-Month Study (vol 76, pg 554, 2015) [J] . Alphs Larry The journal of clinical psychiatry . 2019,第2期

机译：Paliperidone棕榈酸盐的现实世界结果与精神分裂症中的每日口腔抗精神病药疗法相比：随机，开放标签，审查董事会蒙蔽15个月的研究（Vol 76，PG 554,2015）
2. Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Board-Blinded 15-Month Study [J] . Alphs Larry, Benson Carmela, Cheshire-Kinney Kimberly, The journal of clinical psychiatry . 2015,第5期

机译：帕潘立酮棕榈酸酯与精神分裂症患者每日口服抗精神病药物治疗的实际结果：一项随机，开放标签，审查委员会盲目的15个月研究
3. Design and Rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) Study: A Novel Comparative Trial of Once-Monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment for Delaying Time to Treatment Failure in Persons With Schizophrenia [J] . Alphs Larry, Mao Lian, Rodriguez Stephen C., The journal of clinical psychiatry . 2014,第12期

机译：帕潘立酮棕榈酸酯用于证明有效性（PRIDE）研究的设计和原理：每月一次帕潘立酮棕榈酸酯与每日口服抗精神病药物治疗的新型比较试验，用于延迟精神分裂症患者的治疗失败时间
4. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective open-label interventional study [O] . Andreas Schreiner, Asaf Caspi, Paul Bergmans, -1

机译：非急性精神分裂症患者从口服非典型抗精神病药物单一疗法转为帕潘立酮棕榈酸酯每月一次：一项前瞻性开放性干预性研究
5. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study [O] . Andreas Schreiner, Asaf Caspi, Paul Bergmans, 2016

机译：非急性精神分裂症患者从口服非典型抗精神病药物单一疗法转为帕潘立酮棕榈酸酯每月一次：一项前瞻性，开放性，干预性研究

Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Boarda€“Blinded 15-Month Study

著录项

相似文献

相关主题

期刊订阅